Recent advancements of bortezomib in acute lymphocytic leukemia treatment

Acta Haematologica

Volumn 129, Issue 4, 2013, Pages 207-214

  Du, Xiao Li ^a   Chen, Qi ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Acute lymphoblastic leukemia; Bortezomib; Molecular mechanism

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BIM PROTEIN; BORTEZOMIB; CYCLIN D; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FENRETINIDE; IDARUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE 10; MITOGEN ACTIVATED PROTEIN KINASE P38; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; STRESS ACTIVATED PROTEIN KINASE 1; TIPIFARNIB; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID; VINCRISTINE; ALEMTUZUMAB; CLOFARABINE; EPRATUZUMAB; ETOPOSIDE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; NELARABINE; STRESS ACTIVATED PROTEIN KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL SURVIVAL; CHILDHOOD LEUKEMIA; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; FEVER; FLUID RETENTION; FUSION GENE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALAISE; MANTLE CELL LYMPHOMA; MENTAL DISEASE; MULTIPLE MYELOMA; NAUSEA; PERIPHERAL NEUROPATHY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SIGNAL TRANSDUCTION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; WEAKNESS; ADVERSE OUTCOME; CANCER CHEMOTHERAPY; DRUG MECHANISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG THERAPY, COMBINATION; FUSION PROTEINS, BCR-ABL; GASTROINTESTINAL DISEASES; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VALPROIC ACID;

EID: 84871911745     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000345260     Document Type: Review

References (51)

1. Graux C: Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance. Transfus Apher Sci 2011; 44: 183-189.
2. United States Cancer Statistics: 1999-2005 Incidence and Mortality Web-based Report. Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2009. http://www.cdc.gov/uscs (accessed May 28, 2010).
3. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
4. Pui CH: Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc 2010; 109: 777-787.
5. Gokbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009; 46: 64-75.
6. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Campana D, Kun LE, Jeha S, Cheng C, Howard SC, Metzger ML, Bhojwani D, Downing JR, Evans WE, Relling MV: Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 371-382.
7. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M, Loning L, Beier R, Ludwig WD, Ratei R, Harbott J,Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M: Riskadjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2,169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489.
8. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
9. Harned TM, Gaynon PS: Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep 2008; 10: 453-458.
10. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH: Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007; 109: 944-950.
11. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML: Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: therapeutic advances in childhood leukemia consortium study. J Clin Oncol 2010; 28: 648-654.
12. Kane RC, Bross PF, Farrell AT, Pazdur R: Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508-513.
13. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R: Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007; 13: 5291-5294.
14. Wright JJ: Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010; 16: 4094-4104.
15. Curran MP, McKeage K: Bortezomib: a review of its use in patients with multiple myeloma. Drugs 2009; 69: 859-888.
16. Cvek B: Proteasome inhibitors. Prog Mol Biol Transl Sci 2012; 109: 161-226.
17. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC: Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008; 14: 1446-1454.
18. Wang AH, Wei L, Chen L, Zhao SQ, Wu WL, Shen ZX, Li JM: Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. Ann Hematol 2011; 90: 917-931.
19. Nie D, Huang K, Yin S, Li Y, Xie S, Ma L, Wang X, Wu Y, Xiao J: Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells. Leuk Lymphoma 2012; 53: 2487-2495.
20. Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, Sposto R, van der Giessen J, Eckroth E, Bostrom BC: Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer 2010; 55: 254-259.
21. Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J, Bostrom BC: Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia lymphoma (TACL) study. Blood 2012; 120: 285-290.
22. Brown RE, Bostrom B, Zhang PL: Morphoproteomics and bortezomib/ dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann Clin Lab Sci 2004; 34: 203-205.
23. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, Wright J, Kantarjian H: Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10: 3371-3376.
24. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M, Blaney SM: A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a children's oncology group study. Clin Cancer Res 2007; 13: 1516-1522.
25. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J, Smith MA: Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 37-45.
26. Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM: A phase I clinical- pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res 2011; 17: 1140-1146.
27. Luqman S, Pezzuto JM: NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res 2010; 24: 949-963.
28. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C: Transcription factor NF-B is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
29. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT: Nuclear factor B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
30. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC: The proteasome inhibitor PS-potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-2380.
31. Xu JJ, Hu XH, Shen YY, Sun AN, Guo F, He GS: Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia. Zhonghua Xue Ye Xue Za Zhi 2011; 32: 697-698.
32. Szczepanek J, Pogorzala M, Konatkowska B, Juraszewska E, Badowska W, Olejnik I, Kuzmicz M, Stanczak E, Malinowska I,Stefaniak J, Sobol G, Szczepanski T, Czyzewski K, Wysocki M, Styczynski J: Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. Anticancer Res 2010; 30: 2119-2124.
33. Weng AP, Ferrando AA, Lee W, Morris JP 4th, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC: Activating mutations of Notch1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
34. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH, Alt FW, Kelliher M, Look AT: Activating Notch1 mutations in mouse models of T-ALL. Blood 2006; 107: 781-785.
35. Paganin M, Ferrando A: Molecular pathogenesis and targeted therapies for Notch1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011; 25: 83-90.
36. Shin HM, Minter LM, Cho OH, Gottipati S, Fauq AH, Golde TE, Sonenshein GE, Osborne BA: Notch1 augments NF B activity by facilitating its nuclear retention. EMBO J 2006; 25: 129-138.
37. Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, Thompson B, Spaulding C, Macaroun S, Alegre ML,Kee BL, Ferrando A, Miele L, Aifantis I: Targeting the NF B signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13: 70-77.
38. Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J, Rodilla V, Ingles-Esteve J, Nomdedeu J, Bellosillo B, Besses C, Abdel-Wahab O, Kucine N, Sun SC, Song G, Mullighan CC, Levine RL, Rajewsky K, Aifantis I, Bigas A: The Notch/Hes1 pathway sustains NF B activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18: 268-281.
39. Shin DY, Kim I, Kim KH, Choi Y, Beom SH, Yang Y, Lim Y, Lee E, Lee JK, Kim JY, Kim HK, Yoon SS, Lee DS, Park S, Kim BK: Acute lymphoblastic leukemia in elderly patients: a single institution's experience. Korean J Intern Med 2011; 26: 328-339.
40. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka-Schaub G, Bartram CR, Ludwig WD, Riehm H, Lampert F, Harbott J: Incidence and clinical outcome of children with BCR/ABLpositive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on
41. patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996; 10: 957-963.
42. Jagani Z, Singh A, Khosravi-Far R: FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta 2008; 1785: 63-84.
43. Jagani Z, Song K, Kutok JL, Dewar MR, Melet A, Santos T, Grassian A, Ghaffari S, Wu C, Yeckes-Rodin H, Ren R, Miller K, Khosravi-Far R: Proteasome inhibition causes regression of leukemia and abrogates BCRABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res 2009; 69: 6546-6555.
44. Dewar R, Chen ST, Yeckes-Rodin H, Miller K, Khosravi-Far R: Bortezomib treatment causes remission in a Ph + ALL patient and reveals FoxO as a theranostic marker. Cancer Biol Ther 2011; 11: 552-558.
45. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-1534.
46. Lin A, Dibling B: The true face of JNK activation in apoptosis. Aging Cell 2002; 1: 112-116.
47. Verma G, Datta M: The critical role of JNK in the ER-mitochondrial crosstalk during apoptotic cell death. J Cell Physiol 2012; 227: 1791-1795.
48. Luo P, Lin M, Li L, Yang B, He Q: The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway. PLoS One 2011; 6:e27298.
49. Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, Dent P, Grant S: Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther 2009; 8: 808-819.
50. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP: Mechanism of synergy of N-(4-hydroxyphenyl) retinamide and ABT-in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 2008; 100: 580-595.
51. Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ: The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica 2011; 96: 69-77.